FDA Peptide Ban 2026: Which Peptides Are Legal, Restricted, and Coming Back?

If you have been following the peptide space over the past two years, you have watched a regulatory rollercoaster. Peptides that physicians prescribed freely in 2022 became illegal to compound in 2023. Now some of those same peptides may be coming back. The situation changes month to month, and separating what has actually happened from what has been announced requires close attention to FDA rulemaking, not headlines alone.

This article lays out the current legal status of compounded peptides as of April 2026, explains how the FDA's category system works, and covers what patients and prescribers can expect in the coming months. GLP-1 compounding faces similar issues; see Is Compounded Semaglutide Still Legal in 2026? What Patients Need to Know. Approved GLP-1s like Semaglutide for Weight Loss: Complete Guide 2026 are not affected.

What Are FDA Category 1 and Category 2 for Peptides?

The FDA uses a two-category system to evaluate bulk drug substances that compounding pharmacies want to use. Category 1 includes substances that the FDA considers safe enough for compounding while still under review. Category 2 includes substances the FDA has flagged as presenting safety concerns serious enough to block compounding.¹

The distinction matters because it determines whether a 503A pharmacy (a traditional compounding pharmacy operating under a patient-specific prescription) can legally prepare a given peptide. Category 1 peptides can be compounded. Category 2 peptides cannot, unless the FDA grants a specific exception through formal rulemaking.

This system applies specifically to pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. The rules are different for 503B outsourcing facilities, which operate under a separate regulatory framework and face their own set of requirements.

What Is the Difference Between 503A and 503B Pharmacies?

Understanding this distinction is necessary for following the peptide regulation story. The two types of compounding operations serve different purposes and face different rules.

503A vs. 503B Compounding Pharmacies

Feature	503A Pharmacy	503B Outsourcing Facility
Prescription required?	Yes, patient-specific	No, can produce without prescription
FDA registration	State-licensed, not FDA-registered	Must register with FDA
FDA inspections	State pharmacy board	Regular FDA inspections
Batch production	Limited	Can produce in bulk
Current Good Manufacturing Practices (cGMP)	Not required	Required
Category system applies?	Yes (Category 1/2 list)	Separate bulks list

Most patients get their compounded peptides from 503A pharmacies through a prescriber. The Category 1/2 system directly governs what these pharmacies can make.²

Which 19 Peptides Did the FDA Move to Category 2?

On September 29, 2023, the FDA updated its interim policy for bulk drug substances used by 503A pharmacies and placed the following 19 peptides in Category 2, effectively blocking them from compounding:

1. AOD-9604
2. BPC-157^[2]
3. CJC-1295
4. DSIP (Emideltide)
5. Epitalon
6. GHK-Cu (injectable)
7. GHRP-2
8. GHRP-6
9. Ipamorelin acetate
10. Kisspeptin-10
11. KPV
12. LL-37
13. Melanotan II
14. MOTS-C
15. PEG-MGF
16. Selank acetate
17. Semax
18. Thymosin alpha-1^[3]
19. Thymosin beta-4 fragment

The FDA cited "significant safety risks" as the basis for these restrictions. For many of these peptides, the concern was limited human safety data, lack of FDA-approved equivalents, and potential for harm from unregulated compounding.^[1]1 BPC-157 is directly affected; see our BPC-157 dosage guide.

Which Peptides Have Already Been Removed from Category 2?

Before the RFK Jr. announcement, five peptides were removed from Category 2 in September 2024 after their nominators withdrew the nominations. These five are no longer on the restricted list:³

• AOD-9604
• CJC-1295
• Ipamorelin acetate
• Thymosin alpha-1^[3]
• Selank acetate

The removal of these five was a procedural matter (the nominators pulled their submissions), not a policy reversal. But the practical effect is the same: these peptides are no longer Category 2 restricted and can potentially be compounded again under 503A rules.

What Did RFK Jr. Announce About Peptide Reclassification?

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on The Joe Rogan Experience and stated his intention to move 14 of the 19 Category 2 peptides back to Category 1. His stated goal was to make peptides more accessible to patients and to reverse what he described as an overly restrictive FDA approach.⁴

This announcement generated significant attention. But a policy statement on a podcast is not a rule change. As of April 2026, the FDA has not published a formal update to the Category 1 list reflecting Kennedy's announcement. The Pharmacy Compounding Advisory Committee (PCAC) has not completed review of the affected substances.²

The peptides expected to be reclassified back to Category 1 include BPC-157, DSIP, Epitalon, GHK-Cu, GHRP-2, GHRP-6, Kisspeptin-10, KPV, LL-37, Melanotan II, MOTS-C, PEG-MGF, Semax, and Thymosin beta-4 fragment. If all 14 are moved, only 0 of the original 19 would remain in Category 2 (since 5 were already removed).⁵

What Does "Research Use Only" vs. "Prescribed by a Doctor" Mean?

This is one of the most misunderstood areas of peptide law. There are three distinct legal categories for how a peptide can be obtained:

• FDA-approved drug. Manufactured by a pharmaceutical company, FDA-reviewed for safety and efficacy, available by prescription. Examples: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound).
• Compounded medication. Prepared by a licensed pharmacy (503A or 503B) based on a prescriber's order. Uses bulk drug substances. Legal when the substance is on the Category 1 list or otherwise permitted.
• Research chemical. Sold for laboratory use only. Not approved for human use. Not prescribed by a doctor. Purchasing peptides labeled "for research use only" and self-administering them is legally and medically risky.

The distinction matters because some online vendors sell Category 2 peptides as "research chemicals." Buying these products is not the same as getting a prescribed compounded medication from a licensed pharmacy. The quality control, purity testing, and legal protections are completely different.

What Should Patients Currently Using Peptides Do?

If you are currently using a peptide that is on the Category 2 list and have not been able to get it compounded since 2023, the situation may improve in the coming months. What to watch for:

• Formal FDA publication of an updated Category 1 list
• PCAC review dates for specific peptides
• Your compounding pharmacy's announcements about which peptides they can prepare

If you were previously using BPC-157, Semax, Thymosin beta-4, or any other Category 2 peptide under a physician's care, do not source these from unregulated vendors. Wait for legal compounding to resume. The timeline is uncertain, but the direction of policy is toward restoration.

For patients using SEMAGLUTIDE or TIRZEPATIDE, these medications were never on the Category 2 list. Their compounding availability is governed by separate shortage and enforcement discretion rules.

Frequently Asked Questions

Are peptides illegal in the US in 2026?

Not all peptides are illegal. Some (like semaglutide and tirzepatide) are FDA-approved drugs. Others can be legally compounded by 503A pharmacies if they are on the Category 1 list. Fourteen peptides remain restricted under Category 2 as of April 2026, though reclassification has been announced but not yet formalized.

Is BPC-157 legal to prescribe in 2026?

As of April 2026, BPC-157 remains on the FDA's Category 2 list and cannot be legally compounded by 503A pharmacies. HHS Secretary RFK Jr. has announced plans to reclassify it back to Category 1, but the formal FDA rule change has not been published yet.

What is the difference between Category 1 and Category 2 peptides?

Category 1 peptides have sufficient safety data to allow compounding by licensed pharmacies while the FDA continues to evaluate them. Category 2 peptides have been flagged for significant safety concerns and cannot be compounded under standard 503A rules.

Which peptides did RFK Jr. say would be reclassified?

RFK Jr. indicated 14 peptides would move from Category 2 back to Category 1, including BPC-157, DSIP, Epitalon, GHK-Cu, GHRP-2, GHRP-6, Kisspeptin-10, KPV, LL-37, Melanotan II, MOTS-C, PEG-MGF, Semax, and Thymosin beta-4 fragment.

Can I buy research peptides legally?

Peptides sold as "research use only" are not approved for human consumption. While purchasing them may not always be prosecuted, self-administering research chemicals carries significant legal and health risks. These products are not tested to pharmaceutical standards for purity or sterility.^[4]

When will the FDA finalize the peptide reclassification?

No firm timeline has been published. The Pharmacy Compounding Advisory Committee (PCAC) needs to review the affected substances, and the FDA must publish a formal rule change. Based on typical regulatory timelines, this could take several months to over a year from the February 2026 announcement.

Are semaglutide and tirzepatide affected by the peptide ban?

No. Semaglutide and tirzepatide are FDA-approved drugs and were never placed on the Category 2 list. Their compounding availability is governed by separate drug shortage rules and enforcement discretion policies, not the peptide category system.

What are 503A and 503B pharmacies?

503A pharmacies are traditional compounding pharmacies that prepare patient-specific prescriptions under state licensing. 503B outsourcing facilities are FDA-registered, FDA-inspected operations that can produce compounded medications in bulk without patient-specific prescriptions. Both are subject to different regulatory frameworks.

Medical References

1. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. [PubMed]
2. Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert's cytoprotection, Selye's stress coping response, and Lesniewski-Nasil's and Gruner's findings. Curr Pharm Des. 2020;26(25):2985-3000. [PubMed]
3. Tuthill C, Rios I, McBeath R. Thymalfasin: properties and applications. Ann N Y Acad Sci. 2010;1194:130-135. [PubMed]
4. McPherson TB, Fontane PE, Jackson KD, et al. Prevalence of compounding in independent community pharmacy practice. J Am Pharm Assoc. 2006;46(5):568-573. [PubMed]
5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. [FDA.gov]

This article is for educational purposes only and does not constitute medical advice. FormBlends prescribes compounded semaglutide and TIRZEPATIDE through licensed 503A and 503B pharmacy partners. Always consult your physician before starting or stopping any medication.

Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10

Author: FormBlends Medical Team

Related guides

• FDA Registration: What It Actually Means for Peptide Companies in 2026
• Bacteriostatic Water vs Sterile Water: Which to Use for Peptides in 2026
• Peptide Expiration Dates: How Long Do Peptides Last in 2026